Michelle Carr, Author at BioTuesdays

Developments

Hepion to highlight AI-POWR platform at AI webinar

Hepion Pharmaceuticals (NASDAQ:HEPA) will highlight its AI-POWR platform in a presentation during a webinar on March 23 entitled, “How Artificial Intelligence is Changing Drug Discovery.” The webinar is being co-hosted...

March 17, 2023

Developments

OpSens in specialty diagnostics pact with Premier for SavvyWire

OpSens (TSX:OPS; OTCQX:OPSSF) was awarded a national group purchasing agreement for interventional specialty diagnostics with Premier, a leading healthcare improvement company uniting an alliance with approximately...

March 14, 2023

Executive Moves

Dylan Dupuis joins ROTH MKM healthcare research team

Dylan Dupuis, Ph.D., has joined ROTH MKM’s healthcare research team as managing director, senior research analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap...

March 13, 2023

Markets

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

Raymond James raised its price target for Profound Medical (NASDAQ:PROF) to $17 from $15 and reiterated a “strong buy” rating after the company said its application for full CPT-1 reimbursement for TULSA-PRO has been...

March 8, 2023

Developments

LENZ Therapeutics in $83.5-million series B financing to advance presbyopia treatments

LENZ Therapeutics raised $83.5-million in an oversubscribed Series B financing. New investor, Sectoral Asset Management, led the financing and was joined by Alpha Wave Ventures and Point 72, as well as existing...

March 7, 2023

Developments

Hepion’s rencofilstat IP estate strengthened with new European patent

The European Patent Office granted a patent to Hepion Pharmaceuticals (NASDAQ:HEPA) covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat. The newly granted European patent also...

March 2, 2023

Developments

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

The FDA granted orphan drug designation for Aravive’s (NASDAQ:ARAV) batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC). In a statement, Gail McIntyre, Ph.D., DABT, CEO of Aravive, said three...

March 1, 2023

Markets

Research Capital sees Theralase’s Ruvidar NMIBC as potentially better than Keytruda

Research Capital likes the potential chances of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar photodynamic therapy being better than Merck’s Keytruda for treating Bacillus Calmette-Guérin (BCG)-unresponsive...

February 23, 2023

Developments

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) presented interim data from its Phase 2 (Study II) clinical study at the American Society of Clinical Oncology (ASCO) Genito Urinary Cancer Symposium via a moderated poster...

February 23, 2023

Developments

Theralase named to TSXV 2023 Venture 50

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) was named to the TSX Venture Exchange’s 2023 Venture 50, an annual ranking of top-performing companies from five industry sectors. Theralase was recognized in the clean...

February 21, 2023

Author - Michelle Carr

Hepion to highlight AI-POWR platform at AI webinar

OpSens in specialty diagnostics pact with Premier for SavvyWire

Dylan Dupuis joins ROTH MKM healthcare research team

Raymond James, AGP up Profound Medical PTs as AMA to consider CPT approval

LENZ Therapeutics in $83.5-million series B financing to advance presbyopia treatments

Hepion’s rencofilstat IP estate strengthened with new European patent

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

Research Capital sees Theralase’s Ruvidar NMIBC as potentially better than Keytruda

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase named to TSXV 2023 Venture 50

General

More